How to Identify, Treat, and Manage Patients with Multiple Myeloma

 

Penn Medicine Abramson Cancer Center
Avatar

Initial Therapy for MM Including Transplant

By Penn Medicine Abramson Cancer Center FEATURING Alfred Garfall
By Penn Medicine Abramson Cancer Center FEATURING Alfred Garfall
50 views
May 2, 2022
0 Comments
Login to view comments. Click here to Login
How to Identify, Treat, and Manage Patients with Multiple Myeloma
05:27
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Pat…

Feat. A. Perrot
08:55
Laurent Garderet

D-Rd in Transplant-Ineligible NDMM: Results From the MAIA Trial

16:16
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

Frontline Therapy for NDMM: The Role of Transplant, Duration & G…

Feat. A. Krishnan
15:16
SOHO 3rd Italian Conference

SOHO Italy 2021: Newly Diagnosed Transplant-Eligible MM

Feat. V. Montefusco
09:07
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Genomic and Immune Signatures Predict Sustained MRD Negati…

Feat. E. Boyle
19:15
Total Health

Treatment Updates for MM: Risk Stratification's Role in Upfront…

Feat. C. Gleason
18:44
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Enough in NDMM - Triplet …

Feat. K. Shain
13:22
SOHO 3rd Italian Conference

SOHO Italy 2021 on the Importance of Imaging in Novel Agents' E…

Feat. E. Zamagni
06:03
UChicago Medicine 7th Annual Updates from ASH 2021

Post-ASH Case Discussion: 59 y/o Male With Blurry Vision and Develop…

Feat. S. Smith, M. Drazer
19:18
Yale Cancer Center

2021 ASH Updates in Smoldering Myeloma and Newly Diagnosed MM

Feat. E. Gorshein
07:15
Ola Landgren

Awareness Around MRD Testing in Myeloma: Why, When, and How to Test

20:17
Rush University Medical Center

High-Risk Myeloma: Failures and Future Directions

Feat. S. Usmani
20:58
Penn Medicine Abramson Cancer Center

Initial Therapy for MM Including Transplant

Feat. A. Garfall
04:29
ecancer

EHA 2022 on a Phase III GMMG-HD7 Trial: Isa-RVd as Induction Therapy…

Feat. E. Mai
31:36
Nebraska Oncology Society

ASCO 2022 on Moving Toward a Cure in Myeloma: The Role of MRD Testing

Feat. A. Nooka